{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT02268253","nct_id":"NCT02268253","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02268253. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Dose Level 1 - Tagraxofusp - 7 micrograms/kilogram (µg/kg)/day - Chronic Myelomonocytic Leukemia","type":"EXPERIMENTAL"},{"description":null,"label":"Dose Level 2 - Tagraxofusp - 9 µg/kg/day - Chronic Myelomonocytic Leukemia","type":"EXPERIMENTAL"},{"description":null,"label":"Dose Level 3 - Tagraxofusp - 12 µg/kg/day - Chronic Myelomonocytic Leukemia","type":"EXPERIMENTAL"},{"description":null,"label":"Dose Level 1 - Tagraxofusp - 7 µg/kg/day - Myelofibrosis","type":"EXPERIMENTAL"},{"description":null,"label":"Dose Level 2 - Tagraxofusp - 9 µg/kg/day - Myelofibrosis","type":"EXPERIMENTAL"},{"description":null,"label":"Dose Level 3 - Tagraxofusp - 12 µg/kg/day - Myelofibrosis","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-03-27","type":"ACTUAL"},"conditions":["Myelofibrosis","Chronic Myelomonocytic Leukemia"],"enrollment":{"count":82,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tagraxofusp Injection","otherNames":["SL-401","Elzonris"],"type":"DRUG"}],"last_update":"2025-01-06","lead_sponsor":"Stemline Therapeutics, Inc.","official_title":"Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2023-03-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Dose-limiting Toxicities (DLTs)","timeFrame":"21 days of Cycle 1 (21 days/cycle)"},{"measure":"Objective Response Rate (ORR)","timeFrame":"1145 days"}],"references":[{"citation":"Yacoub A, Ali H, Gupta V, Wang ES, Patnaik MM, Schiller GJ, Taparia M, Mughal TI, Lindsay R, Galleu A, Gupta I, Pemmaraju N. Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis. Blood Neoplasia. 2025 Aug 25;2(4):100165. doi: 10.1016/j.bneo.2025.100165. eCollection 2025 Nov.","pmid":"41146971","type":"DERIVED"},{"citation":"Patnaik MM, Ali H, Wang ES, Yacoub A, Foran JM, Gupta V, Schiller GJ, Stevens DA, Talpaz M, Wall S, Lasho TL, Mangaonkar AA, Badar T, Lindsay R, Galleu A, Gupta I, Pemmaraju N, Garcia-Manero G. Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. Blood Neoplasia. 2025 May 11;2(4):100115. doi: 10.1016/j.bneo.2025.100115. eCollection 2025 Nov.","pmid":"40919483","type":"DERIVED"}],"start_date":{"date":"2016-02-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)","url":"https://clinicaltrials.gov/study/NCT02268253"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02268253"}